Leitlinie „Behandlung der Akne“ - AWMF

013/017 - Behandlung der Akne aktueller Stand: 02/2010
korrigierte Fassung: 10/2011
estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled
trial. Obstet Gynecol. 2008; 112: 773-81.
306. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The
effect of 2 combined oral Contraceptives containing either drospirenone or
cyproterone acetate on acne and seborrhea. Cutis. 2002; 69: 2-15.
307. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a
retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol.
2000; 43: 498-502.
308. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo
or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst
Rev. 2009: CD000194.
309. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and
spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil
Steril. 1994; 61: 281-7.
310. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the
treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf). 2002; 57: 231-
34.
311. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann
Pharmacother. 1995; 29: 736-42.
312. Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne
vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi
Xue Za Zhi. 1999; 22: 423-32.
313. Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylostalo P.
Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in
female acne patients treated with two different oral contraceptives. Acta Derm
Venereol. 1984; 64: 517-23.
314. Upton GV, Corbin A. The relevance of the pharmacologic properties of a
progestational agent to its clinical effects as a combination oral contraceptive. Yale J
Biol Med. 1989; 62: 445-57.
315. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a
low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg
of levonorgestrel for the treatment of moderate acne: A randomized, placebocontrolled
trial. J Am Acad Dermatol. 2002; 47: 399-409.
316. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A
randomized, controlled trial of a low-dose contraceptive containing 20 microg of
ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril.
2001; 76: 461-8.
317. Lemay A, Dewailly SD, Grenier R, Huard J. Attenuation of mild hyperandrogenic
activity in postpubertal acne by a triphasic oral contraceptive containing low doses of
ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 1990; 71: 8-14.
318. Henzl MR. Norgestimate. From the laboratory to three clinical indications. J Reprod
Med. 2001; 46: 647-61.
319. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ.
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
J Am Acad Dermatol. 1997; 37: 746-54.
Seite 125 von 136